In the process of generating overexpression cell lines, we often fall into a common misconception: Is it sufficient to rely solely on standard Western blotting to conclusively determine whether the cell line has been successfully established? In practice, however, we frequently encounter challenging situations: even when the fluorescence signal is clearly visible and sequencing confirms that the sequence is entirely correct, the Western blot still fails to detect the expected target band. In such cases, is the failure due to unsuccessful cell line construction, or have we chosen the wrong validation method?

 

Today, we’ll walk through a real-world project case to discuss how to choose the right methods for validating cell line performance, and explore how we navigated the challenges to ultimately confirm the successful establishment of our cell line.

 

I. Case Study: If Everything Is “Correct,” Why Can’t It Be Detected?

Please review the construction project for the “HL60 Cell FUS-ERG Gene Overexpression Polyclonal” case:

 

Target gene: FUS/ERG fusion protein, with a 3×FLAG tag appended to the C-terminus of the protein. No specific WB antibody is available for this fusion protein; therefore, a 3×FLAG-tag–specific antibody will be used for WB-based expression verification.

 

Vector Design: To facilitate intuitive monitoring of expression levels, we have incorporated an mRuby red fluorescent tag into the vector (linked via a P2A element, which ensures nearly 1:1 protein expression levels upstream and downstream), enabling rapid assessment of transfection and expression efficiency through fluorescence.

 

Following the standard experimental protocol, we successfully packaged lentivirus, infected cells, and performed multiple rounds of puromycin-based drug selection to eliminate cells that had not achieved stable transgene integration.

 

At this stage, we first performed fluorescence microscopy, and the results were highly encouraging: nearly all viable cells exhibited robust red fluorescence, indicating that the vector had been successfully integrated into the cellular genome and that the fluorescent protein was being properly expressed. Visually, the efficiency of this construct was quite impressive, with most cells having successfully undergone the intended editing.

 

Next, following the standard validation protocol, we performed Western blotting using a FLAG-tagged antibody to further quantify the expression of the target protein. However, the results presented a significant challenge: neither the wild-type HL60 cells nor the overexpression cell lines we had generated showed the expected ~20 kDa target band.

 

At this point, our first instinct was: could there have been an error in the sequence ligation during vector construction? After all, if the FUS-ERG and the tag sequences were ligated incorrectly, or if a frameshift mutation occurred, the correct protein would naturally fail to be expressed.

 

Therefore, we immediately proceeded to The cell’s genome was subjected to amplified sequencing. We specifically sequenced the entire construct—from FUS-ERG to mRuby—to verify the integrity of the gene. The sequencing results once again surprised us: the entire sequence was completely correct, with no errors in the junctions between FUS-ERG, the 3×FLAG tag, and mRuby; there were no mutations or frameshifts, and all sequences matched our design exactly. However, Western blotting showed no target band at all. What could be the reason? Could it be that our cell line actually failed to be successfully constructed?

 

Clear fluorescent signals indicate that the vector has successfully entered the cells and undergone transcription and translation, with the fluorescent protein functioning normally; perfect sequencing results confirm that the gene sequence is entirely correct, with no sequence-level errors whatsoever.

 

II. Breaking the Impasse: Proteomics Unveils the Hidden Truth

This is strange:

With conventional validation approaches all hitting a dead end, we decided to take a different approach: since antibody-based detection has reached a bottleneck, could we bypass antibodies altogether and detect the protein directly?

 

Therefore, we employed a proteomic (proteomics) approach to analyze the entire proteome of both wild-type and overexpressing cells.

 

This time, the truth has finally come to light:

Proteomic profiling revealed that the target FUS-ERG protein was unequivocally detected in the overexpressing cells, with highly clear results:

• In wild-type HL60 cells, the target FUS-ERG protein was completely undetectable, consistent with its native expression profile.
• Moreover, in the overexpression cells we constructed, the target protein was not only clearly detected, but also exhibited very high protein levels!

This clearly demonstrates that our cell line was, in fact, successfully established long ago. The target protein is already being expressed normally; it’s just that the Western blot method we used previously was unable to detect it.

So why does WB “fail”?

  After our analysis, we found that the problem may lie in On the spatial folding of proteins : After translation is complete, the FUS-ERG fusion protein undergoes a specific conformational folding that completely buries the C-terminal 3×FLAG tag within the protein’s interior. As a result, FLAG-tag–specific antibodies are unable to bind to the epitope, and the target band cannot be detected—effectively, the tag is “hidden” by the protein itself, making it undetectable by our antibodies.

 

III. Considerations: How should one choose the appropriate method for validating overexpressing stable transfectant cell lines?

This case offers important insights: when validating overexpressing cells, there is no single “one-size-fits-all” approach; each validation method has its own specific applications and limitations. Let’s review the commonly used validation methods to help you determine how to make the right choice:

1. Fluorescence Observation: A “Helpful Assistant” for Rapid Initial Screening

Fluorescent labeling is our most commonly used initial screening method, and its advantages are very evident:

• Rapid and intuitive: no cell lysis is required, and no complex experimental procedures are needed—transfection efficiency can be readily assessed at a glance under a fluorescence microscope.
• Real-time monitoring: Allows for intuitive visualization of cellular expression profiles, facilitating assessment of screening progress and enabling timely adjustments to the screening strategy.

 

However, its limitations are also quite apparent: it can only indicate that the fluorescent protein is expressed; it cannot directly confirm the expression status of the target protein, nor can it provide quantitative information.

 

2. Western blotting: a commonly used but limited “routine method”

Western blotting is the most commonly used method for protein verification. Its advantages include well-established procedures, relatively low cost, and the ability to perform both qualitative and semi-quantitative analysis, making it the standard choice in most laboratories. Typically, you can choose either an antibody against the target protein or an antibody against a tag (such as FLAG) for Western blotting. , but it also has quite a few problems:

• High reliance on antibodies: Both the affinity and specificity of antibodies directly affect the results; in many cases, it is not that the protein is not expressed, but rather that the antibody quality is poor and unable to recognize the target.
• Dependence on epitope exposure: As in our case, once the antigenic epitope of a tag or antibody is masked due to protein folding, post-translational modifications, or other factors, the antibody can no longer bind, directly resulting in a “false negative” outcome.

 

3. Sequencing Validation: “Ultimate Verification” at the Nucleic Acid Level

Sequencing is a nucleic acid–level verification that allows us to confirm whether the gene sequence is correct and to detect mutations or frameshifts, thereby ruling out sequence-level errors. However, its limitation is that a correct nucleic acid sequence does not necessarily guarantee detectable protein expression. Sequencing can only verify that the gene sequence is intact; it cannot reflect protein-level aspects such as expression, folding, or post-translational modifications. In short, sequencing can eliminate the possibility of “sequence errors,” but it cannot confirm that the protein is actually expressed.

 

4. Proteomic Profiling: The “Ultimate Solution” for Breaking Through Bottlenecks

When conventional methods all hit a bottleneck, proteomics emerges as our game-changer:

• Antibody-independent: No antibodies against the target protein or its tags are required; proteins are identified directly based on peptide sequences, fundamentally addressing the challenges of poor antibody availability and epitope masking.
• Direct detection of the protein itself: Regardless of how the protein is folded, as long as it is present, we can detect it through peptide fragments generated by enzymatic digestion, without the protein’s spatial structure affecting the results.
• High sensitivity: It can detect low-abundance proteins and provide precise quantitative information, enabling us to accurately assess the efficiency of overexpression.

IV. Final Remarks

This case teaches us that, in validating cell construct assembly, we must never allow ourselves to be constrained by a single assay. When a standard Western blot yields a “negative” result, do not rush to dismiss the entire cell construct as invalid; instead, consider whether our assay may have reached its analytical limits.

 

Only by choosing the right validation method can we truly dispel the fog and reveal the truth of the experiment. This is precisely what our “Building on Success” series seeks to convey: Each challenge we encounter presents an opportunity to refine our experiments and optimize our protocols; the pitfalls we’ve navigated will ultimately translate into invaluable experience that safeguards your research.

 

If you have encountered similar challenges during the construction and validation of overexpression cell lines, please feel free to reach out to us. We at Leman Bio are committed to sharing our expertise to help you avoid unnecessary detours and support your research journey.